As of the latest Form 4 filed Jun 22, 2026.
What Kura Oncology Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 26 most recent filings for KURA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-22 | 2026-06-18 | Leoni Mollie Chief Medical Officer | SSale | −84.9K | $9.82 | $834K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-19 | FORD KATHLEEN Chief Operating Officer | SSale | −2.26K | $9.08 | $20.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-19 | Powl Brian T. Chief Commercial Officer | SSale | −339.00 | $9.21 | $3.12K | Yes (planned) | Form 4 ↗ |
| 2026-05-20 | 2026-05-18 | Bair Teresa Brophy Chief Legal Officer | SSale | −2.26K | $9.38 | $21.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-25 | 2026-03-23 | WILSON TROY EDWARD President and CEO | MExercise | +6.10K | $6.15 | $37.5K | No | Form 4 ↗ |
| 2026-03-20 | 2026-03-18 | Malley Thomas Director | MExercise | +10.0K | $3.12 | $31.2K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Burrows Francis Chief Scientific Officer | SSale | −1.31K | $8.46 | $11.1K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Powl Brian T. Chief Commercial Officer | SSale | −1.57K | $8.46 | $13.3K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Powl Brian T., Chief Commercial Officer | SSale | −4.84K | $8.46 | $41.0K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | FORD KATHLEEN Chief Operating Officer | SSale | −1.81K | $8.46 | $15.3K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Leoni Mollie Chief Medical Officer | SSale | −1.34K | $8.46 | $11.3K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Leoni Mollie, Chief Medical Officer | SSale | −951.00 | $8.46 | $8.05K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Leoni Mollie, Chief Medical Officer | SSale | −2.23K | $8.46 | $18.9K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Leoni Mollie, Chief Medical Officer | SSale | −3.65K | $8.46 | $30.9K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | DOYLE THOMAS JAMES SVP, Finance & Accounting | SSale | −881.00 | $8.46 | $7.45K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | DOYLE THOMAS JAMES, SVP, Finance & Accounting | SSale | −2.23K | $8.46 | $18.8K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | DOYLE THOMAS JAMES, SVP, Finance & Accounting | SSale | −695.00 | $8.46 | $5.88K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | DOYLE THOMAS JAMES, SVP, Finance & Accounting | SSale | −1.11K | $8.46 | $9.43K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | DOYLE THOMAS JAMES, SVP, Finance & Accounting | SSale | −2.23K | $8.46 | $18.8K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Bair Teresa Brophy Chief Legal Officer | SSale | −4.78K | $8.46 | $40.4K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Bair Teresa Brophy, Chief Legal Officer | SSale | −2.33K | $8.46 | $19.8K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-27 | Bair Teresa Brophy, Chief Legal Officer | SSale | −4.10K | $8.46 | $34.7K | No | Form 4 ↗ |
| 2025-12-19 | 2025-12-18 | Burrows Francis Chief Scientific Officer | SSale | −23.7K | $9.78 | $232K | No | Form 4 ↗ |
| 2025-12-19 | 2025-12-18 | Burrows Francis, Chief Scientific Officer | MExercise | +35.0K | $4.80 | $168K | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-09 | Hasnain Faheem Director | SSale | −10.0K | $10.98 | $110K | No | Form 4 ↗ |
| 2025-12-10 | 2025-12-09 | Hasnain Faheem, Director | MExercise | +10.0K | $3.12 | $31.2K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also KURA’s full analysis or the market-wide insider trading feed. The tabs above jump to KURA’s other SEC data.
Source: SEC Form 4 filings for KURA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.